JPH10109023A - Hollow fiber type selective separation membrane - Google Patents
Hollow fiber type selective separation membraneInfo
- Publication number
- JPH10109023A JPH10109023A JP26482696A JP26482696A JPH10109023A JP H10109023 A JPH10109023 A JP H10109023A JP 26482696 A JP26482696 A JP 26482696A JP 26482696 A JP26482696 A JP 26482696A JP H10109023 A JPH10109023 A JP H10109023A
- Authority
- JP
- Japan
- Prior art keywords
- hollow fiber
- membrane
- selective separation
- fiber type
- separation membrane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012528 membrane Substances 0.000 title claims abstract description 189
- 239000012510 hollow fiber Substances 0.000 title claims abstract description 136
- 238000000926 separation method Methods 0.000 title claims abstract description 73
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims abstract description 55
- 210000004369 blood Anatomy 0.000 claims abstract description 55
- 239000008280 blood Substances 0.000 claims abstract description 55
- 238000001914 filtration Methods 0.000 claims abstract description 50
- 229920000642 polymer Polymers 0.000 claims abstract description 39
- 229920002492 poly(sulfone) Polymers 0.000 claims abstract description 33
- 238000000108 ultra-filtration Methods 0.000 claims abstract description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 38
- 235000011187 glycerol Nutrition 0.000 claims description 19
- 102000004169 proteins and genes Human genes 0.000 claims description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- 239000011148 porous material Substances 0.000 claims description 13
- 241000283690 Bos taurus Species 0.000 claims description 12
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 12
- 238000005534 hematocrit Methods 0.000 claims description 10
- 238000007873 sieving Methods 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 230000014759 maintenance of location Effects 0.000 claims description 6
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims description 4
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 34
- 239000000126 substance Substances 0.000 abstract description 17
- 238000000502 dialysis Methods 0.000 abstract description 13
- 238000000746 purification Methods 0.000 abstract description 7
- 238000001223 reverse osmosis Methods 0.000 abstract description 3
- 230000032683 aging Effects 0.000 abstract 1
- 210000004379 membrane Anatomy 0.000 description 124
- 239000002904 solvent Substances 0.000 description 31
- 239000000243 solution Substances 0.000 description 30
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 28
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 22
- 229920006393 polyether sulfone Polymers 0.000 description 18
- 239000004695 Polyether sulfone Substances 0.000 description 16
- 239000002202 Polyethylene glycol Substances 0.000 description 16
- 229920001223 polyethylene glycol Polymers 0.000 description 16
- 239000007788 liquid Substances 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 11
- 229910052757 nitrogen Inorganic materials 0.000 description 11
- 238000009987 spinning Methods 0.000 description 11
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 239000002994 raw material Substances 0.000 description 9
- 238000010438 heat treatment Methods 0.000 description 7
- 230000007423 decrease Effects 0.000 description 6
- 238000000635 electron micrograph Methods 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 6
- 238000007711 solidification Methods 0.000 description 6
- 230000008023 solidification Effects 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 230000037230 mobility Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 238000005345 coagulation Methods 0.000 description 4
- 230000015271 coagulation Effects 0.000 description 4
- 238000005191 phase separation Methods 0.000 description 4
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 3
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000001112 coagulating effect Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000002615 hemofiltration Methods 0.000 description 2
- 229920001600 hydrophobic polymer Polymers 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- -1 polyethylene Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229920006332 epoxy adhesive Polymers 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001891 gel spinning Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000009285 membrane fouling Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Landscapes
- External Artificial Organs (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Artificial Filaments (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明はポリスルホン系高分
子を用いた中空糸型選択分離膜に関する。さらに詳しく
は、各種流体の透析、濾過処理において目詰まりが少な
く、濾過性能が経時的に安定したポリスルホン系高分子
を用いた中空糸型選択分離膜に関する。The present invention relates to a hollow fiber type selective separation membrane using a polysulfone polymer. More specifically, the present invention relates to a hollow fiber type selective separation membrane using a polysulfone-based polymer which is less clogged in dialysis and filtration of various fluids and has stable filtration performance with time.
【0002】[0002]
【従来の技術】これまで、各種溶液やガスなど各種流体
の透析、濾過処理を行うことを目的に、多くの種類の膜
が使用されてきた。これらの膜の大部分は中空糸型選択
分離膜であるが、中空糸型選択分離膜は高価であるた
め、近年これらの膜を再生して再使用されることも多く
なっている。よって、耐薬品性や膜強度等のより優れた
中空糸型選択分離膜が開発されている。2. Description of the Related Art Many types of membranes have been used for the purpose of dialysis and filtration of various fluids such as various solutions and gases. Most of these membranes are hollow fiber type selective separation membranes, but since hollow fiber type selective separation membranes are expensive, these membranes are often regenerated and reused in recent years. Therefore, a hollow fiber type selective separation membrane having more excellent chemical resistance and membrane strength has been developed.
【0003】現在、耐薬品性や膜強度等に優れた素材と
しては、ポリスルホン系、ポリオレフィン系の高分子が
あり、特にポリスルホン系高分子を用いた中空糸型選択
分離膜は、限外濾過、逆浸透、ガス分離、血液浄化膜等
の分野に幅広く用いられている。At present, materials having excellent chemical resistance and membrane strength include polysulfone-based and polyolefin-based polymers. In particular, hollow-fiber-type selective separation membranes using polysulfone-based polymers are available from ultrafiltration, Widely used in fields such as reverse osmosis, gas separation, and blood purification membranes.
【0004】しかし、かようなポリスルホン系高分子を
用いた中空糸型選択分離膜は、ポリスルホン系高分子が
疎水性高分子であるため、膜が汚れ易く、そのため膜の
選択分離性の劣化が生じ易いという欠点を有する。特
に、ポリスルホン系選択分離膜を血液浄化等に用いる場
合には血液中に血球成分や蛋白質が含有されるため、膜
に目詰まりが生じたり、膜表面に蛋白質の吸着や蛋白ゲ
ル層が形成され、血液側境膜での分極蛋白層、いわゆる
2次層が形成される。このように、血液浄化膜として使
用する際には目詰まりを生じることにより溶質の除去性
能が低下したり、2次層が形成されるため濾過流量が低
下してしまう等の問題がある。However, such a hollow fiber type selective separation membrane using a polysulfone-based polymer is liable to be contaminated because the polysulfone-based polymer is a hydrophobic polymer, so that the selective separation of the membrane is deteriorated. It has the disadvantage that it is easy to occur. In particular, when a polysulfone-based selective separation membrane is used for blood purification or the like, since blood cells and proteins are contained in blood, clogging of the membrane occurs, protein adsorption or a protein gel layer is formed on the membrane surface. Thus, a polarized protein layer at the blood lateral membrane, a so-called secondary layer, is formed. As described above, when used as a blood purification membrane, there is a problem that clogging occurs and solute removal performance is reduced, and a secondary layer is formed, so that a filtration flow rate is reduced.
【0005】上記の問題を解決するために種々の提案が
なされている。例えば、特開平1−94902号には、
透析性能に優れ、長期間使用時の濾過速度の経時劣化の
少ないポリスルホン非対称中空糸膜について記載されて
いる。しかし、該膜は濾過ではなく膜に吸着することに
より血液中のβ2-ミクログロブリン(以下、β2-MG)
を除去するものであるため、膜が除去し得るβ2-MG量
には吸着飽和量という限界値が存在する。また、β2-M
Gは除去できたとしても、β2-MG以外の分子量数千〜
数万の有害物質(尿毒症物質)の除去性能は不明であ
り、かかる有害物質が十分に除去されるとはいえない。Various proposals have been made to solve the above problems. For example, in Japanese Patent Application Laid-Open No. 1-94902,
It describes a polysulfone asymmetric hollow fiber membrane which has excellent dialysis performance and has little deterioration over time in filtration rate during long-term use. However, the membrane adsorbs to the membrane rather than being filtered, so that β2-microglobulin (hereinafter, β2-MG) in the blood is absorbed.
Therefore, the amount of β2-MG that can be removed by the membrane has a limit value called the amount of adsorption saturation. Also, β2-M
Even if G can be removed, several thousand molecular weights other than β2-MG
The removal performance of tens of thousands of harmful substances (uremic substances) is unknown, and it cannot be said that such harmful substances are sufficiently removed.
【0006】さらに、特公平5−54373号には、優
れた溶質透過性を有する血液処理用の非対象中空繊維膜
について記載されている。該膜は高い濾過流量において
も優れた透析除去性能、クリアランスを有しているが、
尿素のような低分子物質ですらそのクリアランスが透析
開始時に比べ透析終了時には低下する結果が示されてお
り、β2-MG等の低分子蛋白質の有害物質を安定して除
去し得るとは考えられない。Further, Japanese Patent Publication No. 5-54337 discloses an asymmetric hollow fiber membrane for blood treatment having excellent solute permeability. Although the membrane has excellent dialysis removal performance and clearance even at a high filtration flow rate,
It has been shown that the clearance of even low molecular substances such as urea is lower at the end of dialysis than at the start of dialysis, and it is considered that harmful substances of low molecular proteins such as β2-MG can be removed stably. Absent.
【0007】上記の通り、耐薬品性や膜強度に優れ、且
つ、濾過速度や溶質除去性能が経時的に安定して、特に
血液透析濾過の分野において問題とされるβ2-MG等の
尿毒症物質をも効果的に除去し得る中空糸型選択分離膜
は未だ得られていないのが現状である。As described above, the chemical resistance and the membrane strength are excellent, and the filtration rate and solute removal performance are stable over time, and uremic diseases such as β2-MG which are particularly problematic in the field of hemodiafiltration. At present, a hollow fiber type selective separation membrane capable of effectively removing substances has not yet been obtained.
【0008】[0008]
【発明が解決しようとする課題】本発明者らは、上記の
課題を解決するため、ポリスルホン系高分子を用いた中
空糸型選択分離膜の膜構造について鋭意検討した結果、
特に高分子量域のポリスルホン系高分子で膜を構成する
ことにより、膜の活性表面での目詰まりやいわゆる分極
2次層の生成を抑制でき、その結果、膜の汚れによる性
能劣化を抑えることが可能となることを見出した。DISCLOSURE OF THE INVENTION The present inventors have conducted intensive studies on the membrane structure of a hollow fiber type selective separation membrane using a polysulfone polymer in order to solve the above-mentioned problems.
In particular, by forming the membrane with a polysulfone-based polymer in a high molecular weight region, clogging on the active surface of the membrane and generation of a so-called polarized secondary layer can be suppressed, and as a result, performance degradation due to membrane fouling can be suppressed. I found that it was possible.
【0009】上記に関して、本願発明者らは、高分子領
域のポリスルホン系又はポリエーテルスルホン系高分子
を用いた場合には、紡糸時の膜の凝固性が適度に向上
し、つまり膜凝固の際の核が発生し易く、又発生した核
が成長し易くなることにより、形成された膜の膜表面は
凹凸が少なく、孔の形や大きさがより均一な膜構造が得
られるためと推測するが、これらの裏付けは現時点では
得られていない。In view of the above, the present inventors have found that when a polysulfone-based or polyethersulfone-based polymer in the polymer region is used, the coagulation property of the membrane during spinning is appropriately improved, that is, when the membrane is coagulated. It is presumed that the nuclei are easily generated and the generated nuclei are easily grown, so that the film surface of the formed film has less unevenness and a film structure with more uniform pore shape and size can be obtained. However, no support is available at this time.
【0010】なお、膜の表面構造は電子顕微鏡で観察す
るが、電子顕微鏡が発する熱により膜表面のポリマーが
解けないようにするためには、5000倍が限度であ
る。一方、より詳細な膜表面構造の解析を行うためには
少なくとも数万倍の電子顕微鏡による観察が必要と考え
られ、上記の電子顕微鏡による膜構造の観察は十分とは
いえない。よって、本願においては、膜表面の平滑性を
血液濾過時の溶質透過性及び限外濾過速度の経時安定性
で表すこととした。Although the surface structure of the film is observed with an electron microscope, the limit is 5000 times in order to prevent the polymer on the film surface from being melted by the heat generated by the electron microscope. On the other hand, in order to perform a more detailed analysis of the film surface structure, it is considered necessary to observe at least tens of thousands of times with an electron microscope, and the observation of the film structure with the above-mentioned electron microscope is not sufficient. Therefore, in the present application, the smoothness of the membrane surface is expressed by the solute permeability during blood filtration and the temporal stability of the ultrafiltration rate.
【0011】上記に加え、膜内部を実質的に均一構造と
した場合、モジュール出口での逆濾過による透析液側か
らの異物(例えばエンドトキシン)のコンタミを防ぐこ
とが可能となり、親水性高分子を含む場合に親水性高分
子が膜構造中に閉じ込められてしっかりと固定されるな
どの利点が生じると考えられる。In addition to the above, when the inside of the membrane has a substantially uniform structure, it is possible to prevent contamination of foreign substances (eg, endotoxin) from the dialysate side by back-filtration at the module outlet, thereby reducing the hydrophilic polymer. It is considered that such a case provides an advantage that the hydrophilic polymer is confined in the membrane structure and firmly fixed.
【0012】本願発明は、上記の知見に基づきさらに重
ねて検討した結果、完成したものである。The present invention has been completed as a result of further studies based on the above findings.
【0013】[0013]
【課題を解決するための手段】すなわち、本願発明は、
膜厚が10〜35μm、内径が100〜300μm、空
孔率が50〜85%のポリスルホン系高分子を含む中空
糸型選択分離膜であって、ポリスルホン系高分子のジメ
チルホルムアミド1重量パーセント溶液中の還元粘度が
0.55〜0.85である中空糸型選択分離膜に関す
る。That is, the present invention provides:
A hollow fiber type selective separation membrane containing a polysulfone polymer having a film thickness of 10 to 35 μm, an inner diameter of 100 to 300 μm, and a porosity of 50 to 85%, wherein the polysulfone polymer is in a 1% by weight solution of dimethylformamide. Is a hollow fiber type selective separation membrane having a reduced viscosity of 0.55 to 0.85.
【0014】好適な実施態様においては、本願発明の中
空糸型選択分離膜は親水性高分子を含む。In a preferred embodiment, the hollow fiber type selective separation membrane of the present invention contains a hydrophilic polymer.
【0015】好適な実施態様においては、前記親水性高
分子がポリビニルピロリドンである。[0015] In a preferred embodiment, the hydrophilic polymer is polyvinylpyrrolidone.
【0016】好適な実施態様においては、本願発明の中
空糸型選択分離膜は膜構造保持剤を含む。In a preferred embodiment, the hollow fiber type selective separation membrane of the present invention contains a membrane structure retention agent.
【0017】好適な実施態様においては、前記膜構造保
持剤がグリセリンである。[0017] In a preferred embodiment, the membrane structure-retaining agent is glycerin.
【0018】好適な実施態様においては、5000倍に
拡大して膜表面を観察するとき明らかに認められる孔及
び凹凸が存在せず、且つ、200倍に拡大して膜断面を
観察するとき実質的に均一である。In a preferred embodiment, there are no holes and irregularities that are clearly observed when the film surface is observed at a magnification of 5000 times, and substantially when the film cross section is observed at a magnification of 200 times. Is uniform.
【0019】好適な実施態様においては、本願発明の中
空糸型選択分離膜を充填したモジュールにヘマトクリッ
ト25〜30%、蛋白質濃度6〜7g/dlの牛血液を
流速200ml/minで流し、濾過流速10ml/m
inで血液濾過を行ったときのβ2-ミクログロブリンの
篩い係数に対する、濾過流速50ml/minで血液濾
過を行ったときのβ2-ミクログロブリンの篩い係数の比
が60%以上である。In a preferred embodiment, bovine blood having a hematocrit of 25 to 30% and a protein concentration of 6 to 7 g / dl is passed through a module filled with the hollow fiber type selective separation membrane of the present invention at a flow rate of 200 ml / min. 10ml / m
The ratio of the sieving coefficient of β2-microglobulin when blood filtration is performed at a filtration flow rate of 50 ml / min to the sieving coefficient of β2-microglobulin when blood filtration is performed in 60% or more.
【0020】好適な実施態様においては、本願発明の中
空糸型選択分離膜を充填したモジュールにヘマトクリッ
ト25〜30%、蛋白質濃度6〜7g/dlの牛血液を
流速200ml/minで流し、濾過流速50ml/m
inで血液濾過を行ったときの、濾過開始後10分時点
での限外濾過速度に対する、濾過開始後5時間時点での
限外濾過速度の比が70%以上である。In a preferred embodiment, bovine blood having a hematocrit of 25 to 30% and a protein concentration of 6 to 7 g / dl is passed through a module filled with the hollow fiber type selective separation membrane of the present invention at a flow rate of 200 ml / min. 50ml / m
The ratio of the ultrafiltration rate at 5 hours after the start of filtration to the ultrafiltration rate at 10 minutes after the start of filtration when performing blood filtration in is 70% or more.
【0021】以下、本願発明を詳細に説明する。Hereinafter, the present invention will be described in detail.
【0022】本発明の中空糸膜型選択分離膜の膜厚は1
0〜35μmである。膜厚が10μm未満の場合には膜
の強度が低下し、また膜厚を一定に保つことが困難とな
り生産性が著しく低下する。また、膜厚が35μmを越
える場合には、膜形成時の相分離状態が均一にならない
ために膜内面の平滑性が保てなくなり、その結果血液濾
過時に蛋白分極層の形成を促進し、濾過抵抗を上昇させ
る原因となる。特に大量除水する場合には、限外濾過速
度の経時的な低下の程度が大きくなり、高い透析、濾過
性能の維持が困難となる。好ましい膜厚は15〜35μ
mである。The thickness of the hollow fiber membrane type selective separation membrane of the present invention is 1
0 to 35 μm. When the film thickness is less than 10 μm, the strength of the film is reduced, and it is difficult to keep the film thickness constant, so that productivity is significantly reduced. On the other hand, if the film thickness exceeds 35 μm, the phase separation state at the time of film formation is not uniform, so that the smoothness of the inner surface of the film cannot be maintained. It causes the resistance to rise. In particular, when a large amount of water is removed, the degree of decrease in the ultrafiltration rate over time becomes large, and it becomes difficult to maintain high dialysis and filtration performance. Preferred film thickness is 15 to 35 μm
m.
【0023】本発明の中空糸型選択分離膜の空孔率は5
0%〜85%である。空孔率が50%未満の場合には充
分な溶質の除去性能が得られず、血液浄化用途には不向
きとなり、空孔率が85%を越える場合には中空糸型選
択分離膜の強度が低下することにより生産性が低下す
る。なお、空孔率は膜を1〜2時間水洗後、膜表面に付
着した水(外表面に付着した水及び芯部に残存した水)
を除き、重量を測定し(重量A)、さらに105℃で絶
乾した後、重量を測定し(重量B)、次式により算出し
て求める。 空孔率=(重量A−重量B)/{(重量A−重量B)+
(重量B/ρ)}×100% 但し、ρはポリマーの比重The porosity of the hollow fiber type selective separation membrane of the present invention is 5
0% to 85%. If the porosity is less than 50%, sufficient solute removal performance cannot be obtained, making the composition unsuitable for blood purification applications. If the porosity exceeds 85%, the strength of the hollow fiber type selective separation membrane is reduced. A decrease causes a decrease in productivity. The porosity is determined by measuring the porosity of the membrane after washing with water for 1 to 2 hours, followed by water adhering to the membrane surface (water adhering to the outer surface and water remaining in the core).
The weight is measured (weight A), and after absolute drying at 105 ° C., the weight is measured (weight B) and calculated by the following equation. Porosity = (weight A−weight B) / {(weight A−weight B) +
(Weight B / ρ)} 100% where ρ is the specific gravity of the polymer
【0024】本発明の中空糸型選択分離膜の内径は10
0μm〜300μmである。内径が100μm未満であ
る場合には血液を流した時の圧力損失が大きくなり、血
液にダメージを与え溶血を生じる恐れがあり、また血液
が凝固して中空部に血栓を生じる可能性があり好ましく
ない。内径が300μmを越える場合には中空部が大き
くなりすぎて、中空形状を保つことが困難となり生産性
が低下する。また、中空糸膜内面のせん断速度が小さく
なり濾過に伴い蛋白質等が膜の内面に堆積し易くなる。
好ましい内径は120〜250μmである。The hollow fiber type selective separation membrane of the present invention has an inner diameter of 10
It is 0 μm to 300 μm. When the inner diameter is less than 100 μm, the pressure loss when flowing blood becomes large, which may damage the blood and cause hemolysis, and may cause the blood to coagulate and form a thrombus in the hollow portion. Absent. When the inner diameter exceeds 300 μm, the hollow portion becomes too large, it is difficult to maintain the hollow shape, and the productivity is reduced. In addition, the shear rate on the inner surface of the hollow fiber membrane is reduced, and proteins and the like are easily deposited on the inner surface of the membrane with the filtration.
The preferred inner diameter is between 120 and 250 μm.
【0025】本発明の中空糸型選択分離膜を構成するポ
リスルホン系高分子は、特に限定されるものではなく、
分子中にスルホン基を有する高分子は全て用いることが
できる。ポリスルホン系高分子の例としては、例えばポ
リスルホン(化学式1)、ポリエーテルスルホン(化学
式2)、ポリアリールスルホン等が挙げられる。この中
でもポリエーテルスルホン、ポリスルホンはポリマーの
親水性と疎水性のバランスがよく、膜への蛋白質の吸着
が低いため特に好ましい。The polysulfone polymer constituting the hollow fiber type selective separation membrane of the present invention is not particularly limited.
All polymers having a sulfone group in the molecule can be used. Examples of the polysulfone-based polymer include, for example, polysulfone (chemical formula 1), polyether sulfone (chemical formula 2), polyaryl sulfone, and the like. Among them, polyethersulfone and polysulfone are particularly preferable because the balance between the hydrophilicity and the hydrophobicity of the polymer is good and the adsorption of the protein to the membrane is low.
【0026】[0026]
【化1】 Embedded image
【0027】[0027]
【化2】 Embedded image
【0028】本発明の中空糸型選択分離膜を構成するポ
リスルホン系高分子は、ジメチルホルムアミド1重量%
溶液の還元粘度が0.55〜0.85である。ジメチル
ホルムアミド1重量%溶液の還元粘度が0.55未満の
場合には、得られた中空糸膜の表面平滑性や均一性が悪
く、透析・濾過処理時の膜表面での目詰まりやいわゆる
分極2次層が生じやすくなる。また、膜強度が弱いた
め、ハンドリング性が悪く、生産性が低下する。還元粘
度が0.85を越える場合には、ポリスルホン系又はポ
リエーテルスルホン系高分子の溶解性の低下、紡糸装置
のラインフィルターの背圧上昇によるフィルター寿命の
低下により、生産性が低下する。好ましい還元粘度は
0.6〜0.85である。The polysulfone polymer constituting the hollow fiber type selective separation membrane of the present invention is 1% by weight of dimethylformamide.
The reduced viscosity of the solution is 0.55 to 0.85. When the reduced viscosity of a 1% by weight solution of dimethylformamide is less than 0.55, the obtained hollow fiber membrane has poor surface smoothness and uniformity, and causes clogging and so-called polarization on the membrane surface during dialysis / filtration treatment. A secondary layer is easily formed. Further, since the film strength is weak, the handling property is poor and the productivity is reduced. When the reduced viscosity exceeds 0.85, productivity decreases due to a decrease in solubility of the polysulfone or polyethersulfone polymer and a decrease in filter life due to an increase in back pressure of the line filter of the spinning device. The preferred reduced viscosity is 0.6 to 0.85.
【0029】本願発明において、ポリスルホン系高分子
の還元粘度ηは、乾燥したポリスルホン系高分子をジメ
チルホルムアミドに1重量%となるように溶かした溶液
及び溶媒であるジメチルホルムアミドの粘度η1 及びη
0 をオストワルド型粘度計により測定し、下記の式によ
り計算して求めた値をいう。 η=((η1 −η0 )/η0 )/c η0 :溶媒の粘度 η1 :溶液の粘度 c :溶質の濃度(g/dl) なお、中空糸膜を構成するポリスルホン系高分子の還元
粘度は、膜がポリスルホン系高分子のみからなる場合
は、上記の通り測定し求めてもよいが、他の高分子を含
む場合を含め本願においては、中空糸膜中のポリスルホ
ン系高分子の還元粘度は以下の通り求める。まず、中空
糸膜をジメチルホツムアミドに溶かし試料溶液とする
(還元粘度:X)。次に、還元粘度が約0.5及び約
0.8の還元粘度が既知の2種類のポリエーテルスルホ
ンをジメチルホルムアミドに溶かし標準溶液1及び標準
溶液2とする(還元粘度:A、B)。標準溶液1、2及
び試料溶液を用いてジメチルホルムアミドを移動層とす
るゲル濾過を行い、それぞれの移動度を求める(移動
度:a、b、x)。下記の式により、試料溶液中のポリ
スルホン系高分子の還元粘度(X)を求める。 X=B−(B−A)×(b−x)/(b−a) 但し、X:中空糸膜中のポリスルホン系高分子の還元粘
度 A:還元粘度が約0.5のポリエーテルスルホンの還元
粘度 B:還元粘度が約0.8のポリエーテルスルホンの還元
粘度 x:中空糸膜中のポリスルホン系高分子の移動度 a:還元粘度が約0.5のポリエーテルスルホンの移動
度 b:還元粘度が約0.8のポリエーテルスルホンの移動
度 本願発明においては、かようにして求めたXを中空糸膜
中のポリスルホン系高分子の還元粘度とする。In the present invention, the reduced viscosity η of the polysulfone polymer is determined by measuring the viscosity η1 and η of the solution of the dried polysulfone polymer dissolved in dimethylformamide at 1% by weight and the solvent dimethylformamide.
0 is a value measured by an Ostwald viscometer and calculated by the following equation. η = ((η1−η0) / η0) / c η0: viscosity of solvent η1: viscosity of solution c: concentration of solute (g / dl) The reduced viscosity of the polysulfone polymer constituting the hollow fiber membrane is When the membrane is composed of only a polysulfone-based polymer, it may be measured and determined as described above, but in the present application including the case where the polymer contains other polymers, the reduced viscosity of the polysulfone-based polymer in the hollow fiber membrane is as follows: Ask as follows. First, a hollow fiber membrane is dissolved in dimethylfomamide to prepare a sample solution (reduced viscosity: X). Next, two kinds of polyether sulfones having reduced viscosities of about 0.5 and about 0.8 and having known reduced viscosities are dissolved in dimethylformamide to prepare standard solutions 1 and 2 (reduced viscosities: A and B). Gel filtration is performed using dimethylformamide as a mobile layer using the standard solutions 1 and 2 and the sample solution to determine the respective mobilities (mobilities: a, b, x). The reduced viscosity (X) of the polysulfone-based polymer in the sample solution is determined by the following equation. X = B− (BA) × (b−x) / (ba) where X: reduced viscosity of polysulfone polymer in hollow fiber membrane A: polyether sulfone having reduced viscosity of about 0.5 B: Reduced viscosity of polyethersulfone having a reduced viscosity of about 0.8 x: Mobility of polysulfone-based polymer in hollow fiber membrane a: Mobility of polyethersulfone having a reduced viscosity of about 0.5 b : Mobility of polyether sulfone having a reduced viscosity of about 0.8 In the present invention, X thus obtained is defined as the reduced viscosity of the polysulfone polymer in the hollow fiber membrane.
【0030】本発明の中空糸型選択分離膜は、親水性高
分子を含むことが好ましい。親水性高分子の種類は特に
限定されるものではないが、例えばポリビニルピロリド
ン、ポリビニルアルコール、ポリエチレングリコールな
どが挙げられる。中でも、ポリビニルピロリドンは、ポ
リスルホン系高分子との相溶性がよく、膜の親水性を高
める上で特に好ましい。なお、これらの親水性高分子に
は重合度によりいくつかの種類が存在し、どの分子量の
ものでも使用できるが、分子量が高いほど膜外への溶出
が起こりにくいため、分子量の高いものを使用すること
が望ましい。The hollow fiber type selective separation membrane of the present invention preferably contains a hydrophilic polymer. The type of the hydrophilic polymer is not particularly limited, and examples thereof include polyvinyl pyrrolidone, polyvinyl alcohol, and polyethylene glycol. Above all, polyvinylpyrrolidone has good compatibility with the polysulfone-based polymer, and is particularly preferable for enhancing the hydrophilicity of the membrane. There are several types of these hydrophilic polymers depending on the degree of polymerization, and any type of molecular weight can be used.However, the higher the molecular weight, the more difficult the elution out of the membrane to occur. It is desirable to do.
【0031】本発明の中空糸型選択分離膜は、膜構造保
持剤を含むことが好ましい。膜構造保持剤としては、多
価アルコールが好ましく、例えば、グリセリン、エチレ
ングリコール、プロピレングリコール等が挙げられる。
中でも、グリセリンは、安全性やコストの面から特に好
ましい。The hollow fiber type selective separation membrane of the present invention preferably contains a membrane structure retention agent. Polyhydric alcohol is preferable as the membrane structure-retaining agent, and examples thereof include glycerin, ethylene glycol, and propylene glycol.
Among them, glycerin is particularly preferable in terms of safety and cost.
【0032】本発明の中空糸型選択分離膜の膜表面は、
5000倍の電子顕微鏡で拡大して観察するとき、明ら
かに認められる孔及び凹凸が存在しない。つまり、本願
の中空糸型選択分離膜の膜表面は実質的に平滑であり、
平滑であるが故に膜の目詰まりやいわゆる2次層の生成
を抑え、限外濾過速度や溶質の分離性能が経時的に安定
することとなる。なお、5000倍の電子顕微鏡で観察
するとき明らかに認められる孔が存在しないとは、50
00倍の拡大写真で直径0.2mm以上の孔、つまり内
表面に400オングストローム以上の孔が存在しないこ
とをいい、また5000倍の電子顕微鏡で観察するとき
明らかに認められる凹凸が存在しないとは、5000倍
の拡大写真で1mmのサイズの凹凸、つまり内表面に
0.2μm以上の凹凸が実質的に存在しないことをい
う。The hollow fiber type selective separation membrane of the present invention has a membrane surface
When observed under an electron microscope at 5000 × magnification, there are no clearly recognized holes and irregularities. That is, the membrane surface of the hollow fiber type selective separation membrane of the present application is substantially smooth,
Because of the smoothness, clogging of the membrane and generation of a so-called secondary layer are suppressed, and the ultrafiltration rate and the solute separation performance are stabilized over time. In addition, the fact that there is no hole clearly observed when observed with an electron microscope at 5000 times means that 50
It means that there is no hole with a diameter of 0.2 mm or more, that is, a hole with a diameter of 400 Å or more on the inner surface in an enlarged photograph of 00 times, and that there is no unevenness clearly observed when observed with a 5000 times electron microscope. This means that there is substantially no unevenness having a size of 1 mm in an enlarged photograph of 5000 times, that is, 0.2 μm or more on the inner surface.
【0033】本発明の中空糸型選択分離膜の膜断面は、
200倍に電子顕微鏡で拡大して観察するとき、実質的
に均一構造である。膜内部が不均一構造である場合に
は、膜による分離が膜表面のみで行われるため、膜表面
に部分的な欠陥や分離時のゆらぎのようなものが生じた
場合、膜はその部分を中心に目詰まりが進行し易くな
り、特に大量の血球や蛋白質を含有する血液を濾過する
場合にはこれらの成分の目詰まりへの影響は非常に大き
いものとなる。これに対し、均一膜は膜全体で濾過を支
えるため、膜表面の一部に前記のような欠陥がある場合
にも膜全体でかかる欠陥をカバーし、上記のような目詰
まりを抑制し得る。つまり、膜が均一構造である場合に
は膜の内部構造全体で濾過を支え安定した透析濾過性能
を発現し得る。なお、ここで膜の内部が実質的に均一構
造であるとは、中空糸膜がその径方向及び断面方向に非
対称性を有せず、また、単に径方向に対称なだけなく、
実質的に膜の厚み部分にホモジニアスな多孔構造をとる
ことを意味する。従って、本願発明の中空糸型選択分離
膜の場合、水洗し、膜構造を保持するように凍結乾燥し
て顕微鏡で観測した場合、膜の断面構造はフィンガーラ
イク構造や網目構造などの組織が観測されない均一構造
として観測されることを意味する。The cross section of the hollow fiber type selective separation membrane of the present invention is as follows:
When observed under an electron microscope at a magnification of 200 times, the structure is substantially uniform. When the inside of the film has a non-uniform structure, the separation by the film is performed only on the film surface.If a partial defect or fluctuation at the time of separation occurs on the film surface, the film Clogging is likely to progress at the center, and particularly when filtering blood containing a large amount of blood cells or proteins, the influence of these components on clogging becomes very large. On the other hand, since a uniform membrane supports filtration in the entire membrane, even when there is a defect as described above in a part of the membrane surface, the entire membrane can cover such a defect and suppress the clogging as described above. . That is, when the membrane has a uniform structure, the entire internal structure of the membrane can support filtration and exhibit stable diafiltration performance. Here, that the inside of the membrane has a substantially uniform structure means that the hollow fiber membrane does not have asymmetry in its radial direction and cross-sectional direction, and is not merely symmetrical in the radial direction,
This means that a homogeneous porous structure is formed substantially in the thickness portion of the film. Therefore, when the hollow fiber type selective separation membrane of the present invention is washed with water, freeze-dried so as to retain the membrane structure, and observed with a microscope, the cross-sectional structure of the membrane is observed as a finger-like structure or a network structure. Means that it is observed as a non-uniform structure.
【0034】さらに、膜が不均一構造である場合には、
例えば膜が疎水性ポリマーと親水性ポリマーから形成さ
れている場合、膜中の親水性ポリマーが膜の大きな孔の
部分からから流出し、膜性能の変化や膜からの溶出物が
多く問題となる場合があるが、膜が均一構造である場合
には、膜内の親水性高分子は膜組織中に閉じこめられた
形となるのでしっかりと固定され、上記のような問題も
生じることはない。また、不均一膜で膜の外側の孔径が
大きい場合、透析液側から異物がコンタミしてくるよう
な危険性があるが、均一膜ではかかる危険性もない等の
利点がある。Further, when the film has a non-uniform structure,
For example, when the membrane is formed of a hydrophobic polymer and a hydrophilic polymer, the hydrophilic polymer in the membrane flows out from the large pores of the membrane, and changes in membrane performance and elutions from the membrane cause many problems. In some cases, when the membrane has a uniform structure, the hydrophilic polymer in the membrane is trapped in the membrane tissue and is firmly fixed, and the above-described problem does not occur. In addition, in the case of a nonuniform membrane having a large pore diameter outside the membrane, there is a risk that foreign substances may contaminate from the dialysate side, but there is an advantage that a uniform membrane does not have such a risk.
【0035】此のような均一膜では、中空糸を充填率5
5%で充填した膜面積1.5m2 のモジュールに抗凝固
剤を添加した牛血液を中空糸膜の内側、あるいは、外側
に流速200ml/minで流し、血液濾過を行った場
合のモジュールあたりの限外濾過速度(ml/min・
mmHg)が膜の内外表面で実質的に差が生じないこと
からも確認できる。なお、本発明の中空糸型選択分離膜
は血液浄化処理時透析液側の膜表面も平滑構造であるの
で、透析液側からのコンタミを防止でき、濾過物資をス
ムーズに透析液に移動できる。In such a uniform membrane, the hollow fiber is filled at a filling rate of 5%.
Bovine blood with an anticoagulant added to a module with a membrane area of 1.5 m 2 filled with 5% is flowed inside or outside the hollow fiber membrane at a flow rate of 200 ml / min to perform blood filtration. Ultrafiltration rate (ml / min
mmHg) can be confirmed from the fact that there is substantially no difference between the inner and outer surfaces of the film. In addition, since the hollow fiber type selective separation membrane of the present invention also has a smooth membrane surface on the dialysate side during the blood purification treatment, contamination from the dialysate side can be prevented, and the filtrate can be smoothly transferred to the dialysate.
【0036】本発明の中空糸型選択分離膜を充填したモ
ジュールにヘマトクリット25〜30%、蛋白質濃度6
〜7g/dlの牛血液を流速200ml/minで流し
血液濾過を行う時、濾過速度を10ml/minとした
場合のβ2-MG(分子量:11,600)の篩い係数に
対する、濾過速度を50ml/minとした場合のβ2-
MGの篩い係数の比が60%以上である。この比が60
%未満の場合には、大量除水療法時にβ2-MGをはじめ
とする分子量が数千から数万の尿毒症物質の除去率が不
十分となり、大量除水療法による改善効果が十分に得ら
れないからである。好ましい比は65%以上である。The module filled with the hollow fiber type selective separation membrane of the present invention has a hematocrit of 25 to 30% and a protein concentration of 6
牛 7 g / dl of bovine blood at a flow rate of 200 ml / min to perform blood filtration, the filtration rate was 50 ml / min for the sieving coefficient of β2-MG (molecular weight: 11,600) when the filtration rate was 10 ml / min. β2-
The ratio of the sieving coefficient of MG is 60% or more. This ratio is 60
%, The removal rate of thousands or tens of thousands of uremic substances having a molecular weight of β2-MG or the like during the large-scale water removal therapy becomes insufficient, and the improvement effect by the large-scale water removal therapy is sufficiently obtained. Because there is no. The preferred ratio is at least 65%.
【0037】なお、本発明のかかる規定で用いられる牛
血液の蛋白質濃度及びヘマトクリットの限外濾過速度に
及ぼす影響は大きく、本発明においてはハイパフォーマ
ンス・メンブラン研究会ワーキンググループによりまと
められた膜の性能評価法で、評価にはヘマトクリット値
が25%〜30%、蛋白質濃度が6〜7g/dlの37
℃の牛血液であることとの記載内容を参考にして定め
た。The effect of the present invention on the protein concentration of bovine blood and the rate of ultrafiltration of hematocrit used in the present invention is large, and in the present invention, the performance evaluation of the membrane summarized by the Working Group of the High Performance Membrane Research Society was conducted. Method, the hematocrit value was 25% to 30% and the protein concentration was 6 to 7 g / dl.
It was determined with reference to the description that the blood was bovine blood at ° C.
【0038】本発明の中空糸型選択分離膜を充填したモ
ジュールにヘマトクリット25〜30%、蛋白質濃度6
〜7g/dlの牛血液を流速200ml/minで流し
血液濾過を行う時、濾過速度を10ml/minとした
場合のβ2-MGの篩い係数は0.5以上であることが好
ましい。β2-MGの篩い係数が0.5未満の場合、HF
やHDF治療でβ2-MGをはじめとする分子量が数千か
ら数万の尿毒症物質の除去効率が低く、十分な治療効果
が得られないためである。より好ましいβ2-MGの篩い
係数は0.55以上である。The module filled with the hollow fiber type selective separation membrane of the present invention has a hematocrit of 25 to 30% and a protein concentration of 6
When bovine blood of 77 g / dl is flowed at a flow rate of 200 ml / min to perform blood filtration, the sieving coefficient of β2-MG is preferably 0.5 or more when the filtration rate is 10 ml / min. When the sieving coefficient of β2-MG is less than 0.5, HF
This is because the efficiency of removing uremic substances having a molecular weight of thousands to tens of thousands including β2-MG in HDF treatment is low, and a sufficient therapeutic effect cannot be obtained. More preferably, the sieving coefficient of β2-MG is 0.55 or more.
【0039】本発明の中空糸型選択分離膜を充填したモ
ジュールにヘマトクリット25〜30%、蛋白質濃度6
〜7g/dlの牛血液を流速200ml/minで流し
濾過速度を50ml/minとして血液濾過を行う時、
血液濾過開始後10分時点の限外濾過速度に対する、血
液濾過開始後5時間時点の限外濾過速度の比は70%以
上である。この比が70%未満の場合には、目詰まりに
よる濾過効率の低下が大きい上に、除去性能が低下する
ためである。The module filled with the hollow fiber type selective separation membrane of the present invention has a hematocrit of 25 to 30% and a protein concentration of 6
77 g / dl of bovine blood at a flow rate of 200 ml / min and a filtration rate of 50 ml / min for blood filtration.
The ratio of the ultrafiltration rate 5 hours after the start of hemofiltration to the ultrafiltration rate 10 minutes after the start of hemofiltration is 70% or more. If the ratio is less than 70%, the filtration efficiency is greatly reduced due to clogging, and the removal performance is reduced.
【0040】本発明の中空糸型選択分離膜は、例えば以
下のように製造することができるが、本発明は何等以下
に限定されるものではない。紡糸原液は、ポリマーある
いは複数のポリマーの組み合わせと溶媒あるいは複数の
溶媒の組み合わせ、及び、非溶媒あるいは複数の非溶媒
の組み合わせからなる。紡糸原液中での組成としては、
総ポリマーの重量分率は15〜35重量%が適切であ
り、15%以下では紡糸原液の粘度が低いため可紡性が
低く、35%以上では相分離が早くなりすぎる。総溶媒
分率は30〜70重量%、総非溶媒分率は5〜50重量
%が好ましい。上記の紡糸原液を室温〜190℃に加熱
して均一に溶解させた後、脱気・濾過した後に、二重管
紡糸口の外側から押し出し、中央からは50〜160℃
に加熱した乾燥気体を一定速度で供給する。押し出され
た紡糸原液は1〜20mmの一定距離空中を走行させた
後、5〜60℃の凝固性液体中を通って凝固され、膜構
造を形成する。これを水洗した後、膜構造を保持させる
ため30〜60重量%のグリセリン水溶液中を通らせ、
グリセリンを含浸させた後、乾燥機にて乾燥させ、巻き
取る。The hollow fiber type selective separation membrane of the present invention can be produced, for example, as follows, but the present invention is not limited to the following. The spinning dope comprises a polymer or a combination of a plurality of polymers and a solvent or a combination of a plurality of solvents, and a non-solvent or a combination of a plurality of non-solvents. As the composition in the spinning solution,
The weight fraction of the total polymer is suitably from 15 to 35% by weight. If it is less than 15%, the spinning solution has a low viscosity and the spinnability is low, and if it is 35% or more, the phase separation is too fast. The total solvent fraction is preferably 30 to 70% by weight, and the total non-solvent fraction is preferably 5 to 50% by weight. The above spinning stock solution is heated to room temperature to 190 ° C to uniformly dissolve, then degassed and filtered, and then extruded from the outside of the double-tube spinning port, and 50 to 160 ° C from the center.
Is supplied at a constant rate. The extruded spinning solution is allowed to travel in the air at a fixed distance of 1 to 20 mm, and then coagulated in a coagulating liquid at 5 to 60 ° C. to form a membrane structure. After washing with water, it is passed through a 30 to 60% by weight aqueous glycerin solution to maintain the membrane structure,
After impregnating with glycerin, it is dried in a drier and wound up.
【0041】上記で使用する溶媒としてはいわゆる非プ
ロトン性の極性溶媒、N,N−ジメチルホルムアミド、
N,N−ジメチルアセトアミド、γ−ブチロラクトン、
N−メチルピロリドンなどを単独又は混合して用いる。
非溶媒としては、無機塩やアルコール類などが挙げられ
るが、グリセリン、エチレングリコール、トリエチレン
グリコール、ポリエチレングリコールなどのグリコール
類を単独又は混合して使用するのが好ましい。特に非溶
媒は、相分離のコントロールに重要であり、例えばグリ
セリンを共存させて。相分離を抑制するのが好ましい。
凝固性液体としては水、又は、水と紡糸原液で用いた溶
媒並びに非溶媒の混合水溶液が使用できる。Examples of the solvent used above include a so-called aprotic polar solvent, N, N-dimethylformamide,
N, N-dimethylacetamide, γ-butyrolactone,
N-methylpyrrolidone or the like is used alone or in combination.
Examples of the non-solvent include inorganic salts and alcohols, and it is preferable to use glycols such as glycerin, ethylene glycol, triethylene glycol and polyethylene glycol alone or as a mixture. In particular, the non-solvent is important for controlling phase separation, for example, in the presence of glycerin. Preferably, phase separation is suppressed.
As the coagulable liquid, water or a mixed aqueous solution of water and a solvent used in the spinning solution and a non-solvent can be used.
【0042】なお、本願発明において、膜の内表面の孔
サイズを小さく均一とし、滑らかな表面状態を得るため
に、中空形成剤として気体を用いる乾湿式紡糸法により
製膜されることが好ましい。ここで、用いる気体として
は例えば窒素、ヘリウム、空気等が挙げられるが、品質
と供給の安定性から窒素を用いるのが好ましい。また、
上記で表面状態の平滑性をより向上し、血液透析濾過等
における透水性、分離性及びこれらの保持率をより向上
させるために、中空形成剤として用いる気体の温度を凝
固性液体の温度より20℃以上高くすることが特に好ま
しい。さらに、中空糸は実質的に無延伸で紡糸するこ
と、つまり強制的な延伸を行わずに中空糸の引き取りに
必要な力だけでもって巻取るのが好ましい。膜に形成さ
れる孔の変形を抑えるためである。なお、ここで実質的
に無延伸であるとは紡糸の各工程において10%以上延
伸しないことをいう。In the present invention, in order to make the pore size on the inner surface of the membrane small and uniform and to obtain a smooth surface state, the membrane is preferably formed by a dry-wet spinning method using gas as a hollow forming agent. Here, the gas to be used includes, for example, nitrogen, helium, air and the like, but it is preferable to use nitrogen from the viewpoint of quality and supply stability. Also,
In order to further improve the smoothness of the surface state as described above, and to further improve the water permeability and separation properties in hemodiafiltration and the like and the retention thereof, the temperature of the gas used as the hollow forming agent is set to be 20 degrees lower than the temperature of the coagulable liquid. It is particularly preferable to raise the temperature by at least 0 ° C. Further, it is preferable that the hollow fiber is spun substantially without drawing, that is, it is wound up with only a force necessary for taking up the hollow fiber without forcibly drawing. This is for suppressing deformation of the holes formed in the film. Here, "substantially non-stretching" means that the film is not stretched by 10% or more in each step of spinning.
【0043】本発明の中空糸型選択分離膜のβ2-MGの
SCとUFR(B) は下記の方法により測定する。本発明
の中空糸型選択分離膜が中空糸膜の場合、5000〜2
0000本の中空糸膜をプラスチック成型品の中に入れ
モジュールを作製する。このモジュールを生理食塩水で
洗浄した後に、血液側には前述の牛血液を200ml/
分で流す。モジュールの膜面積1.5m2 当たりの濾過
流速10又は50ml/分となるようにモジュール血液
側の入口及び出口の圧力もしくは透析液側の圧力を調整
し、血液濾過を行い下記について測定する。The SC and UFR (B) of β2-MG of the hollow fiber type selective separation membrane of the present invention are measured by the following methods. When the hollow fiber type selective separation membrane of the present invention is a hollow fiber membrane,
0000 hollow fiber membranes are placed in a plastic molded product to produce a module. After this module was washed with physiological saline, the above-mentioned bovine blood was placed on the blood side at 200 ml / vol.
Pour in minutes. The pressure at the inlet and outlet on the module blood side or the pressure on the dialysate side is adjusted so as to give a filtration flow rate of 10 or 50 ml / min per 1.5 m 2 of membrane area of the module.
【0044】1.β2-MGのSC 濾過速度10又は50ml/分で血液濾過開始後15分
時点のモジュールの入口と出口の血液及び濾過液をサン
プリングして、酵素免疫測定法(例えば、グラザイムβ
2-Microglobulin-EIA Test 和光純薬工業)等によりβ
2-MGの濃度を測定する。なお、当該測定でモジュール
に流す牛血液には適量のヒト由来β2-MGを添加して行
い、サンプリングした血液は必要に応じて遠心分離して
β2-MGの測定に供する。これらのβ2-MGの濃度の値
から下記の式1に従ってβ2-MGのSCを求める。 SC=Cfil /((CI +CO )/2) (式1) Cfil :濾過液のβ2-MG濃度 CI :モジュール血液側入口の血液のβ2-MG濃度 CO :モジュール血液側出口の血液のβ2-MG濃度1. β2-MG SC At a filtration rate of 10 or 50 ml / min, blood and filtrate at the inlet and outlet of the module at 15 minutes after the start of blood filtration are sampled and subjected to enzyme immunoassay (eg, Glazyme β).
Β by 2-Microglobulin-EIA Test Wako Pure Chemical Industries, Ltd.
Measure the concentration of 2-MG. In this measurement, a suitable amount of human-derived β2-MG is added to bovine blood flowing to the module in the measurement, and the sampled blood is centrifuged, if necessary, for measurement of β2-MG. From these β2-MG concentration values, the SC of β2-MG is determined according to the following equation 1. SC = Cfil / ((CI + Co) / 2) (Equation 1) Cfil: β2-MG concentration of filtrate CI: β2-MG concentration of blood at inlet of module blood side CO: β2-MG of blood at outlet of module blood side concentration
【0045】2.UFR(B) の保持率 濾過速度50ml/分で血液濾過開始後15分時点及び
5時間時点のモジュールの血液側の入口と出口及び濾過
液側の圧力を測定する。これらの圧力の値から下記の式
2に従ってUFR(B) を求め、血液透析開始後15分時
点のUFR(B) に対する5時間時点のUFR(B) の比
(UFR(B) の保持率)を求める。 UFR(B) =Qf /(A×((PI +PO )/2−Pfil )) (式2) Qf :限外濾過速度(ml/時) A :膜の表面積(m2 ) PI :モジュール血液側入口の圧力(mmHg) PO :モジュール血液側出口の圧力(mmHg) Pfil :モジュール濾過液側の圧力(mmHg)2. UFR (B) retention The pressures at the inlet and outlet on the blood side and the filtrate side of the module at 15 minutes and 5 hours after the start of blood filtration at a filtration rate of 50 ml / min are measured. UFR (B) was calculated from these pressure values according to the following equation 2, and the ratio of UFR (B) at 5 hours to UFR (B) at 15 minutes after the start of hemodialysis (retention rate of UFR (B)) Ask for. UFR (B) = Qf / (A × ((PI + PO) / 2-Pfil)) (Equation 2) Qf: Ultrafiltration speed (ml / hour) A: Surface area of the membrane (m 2 ) PI: Module blood side Inlet pressure (mmHg) PO: pressure at module blood side outlet (mmHg) Pfil: pressure at module filtrate side (mmHg)
【0046】[0046]
【実施例】以下、実施例を挙げて、具体的に本発明を説
明するが、本発明はこれらに何等限定されるものではな
い。EXAMPLES The present invention will be specifically described below with reference to examples, but the present invention is not limited to these examples.
【0047】(実施例1)ジメチルホルムアミド1重量
%溶液の還元粘度が0.62のポリエーテルスルホンが
20重量%、ポリビニルピロリドン(K−90)が5重
量%、溶媒としてN−メチル−2−ピロリドン37.5
重量%、非溶媒としてポリエチレングリコール#200
が37.5重量%からなる原料を110℃に加熱して溶
かした溶液を、二重管状紡糸口の外側から押し出し、中
心からは80℃に加熱された窒素を送り込んで中空糸状
として、空気中を7mm走行させた後、水、N−メチル
−2−ピロリドン、ポリエチレングリコール#200が
70:15:15の重量比で混合して成る15℃の凝固
性液体中を通過させ、凝固を完了した。その後、水洗
し、50重量%のグリセリンを含浸させた後、乾燥機に
て乾燥して内径201μm、膜厚21μm、空孔率78
%の中空糸膜を得た。該中空糸膜の内表面及び外表面を
電子顕微鏡(以下、SEM)で観察したところ、それぞ
れ第3図及び第4図に示すように内表面及び外表面は共
に5000倍の倍率でも孔及び凹凸の認められない平滑
構造であった。また、該中空糸膜を第1図に示すA−A
線に沿って切断した断面(第2図)の一部(第2図の囲
い線Bの内部)を200倍の倍率で観察したところ、第
5図に示すように膜内部は組織像が観察されず均一構造
であることが確認された。該中空糸膜8400本をプラ
スチック成型品の中に収納して、両端をエポキシ系接着
剤により硬化・固定してモジュールとした。得られたモ
ジュールの中空糸膜の内側に37℃の血液(ヘマトクリ
ット値28%、蛋白質濃度7g/dl)を流量200m
l/分にて導入して、中空糸膜の性能を評価した。結果
は表1に示す通りであった。Example 1 20% by weight of a polyether sulfone having a reduced viscosity of 0.62 in a 1% by weight solution of dimethylformamide, 5% by weight of polyvinylpyrrolidone (K-90), and N-methyl-2- as a solvent Pyrrolidone 37.5
% By weight, polyethylene glycol # 200 as non-solvent
Is heated from 110.degree. C. to a solution obtained by dissolving a raw material consisting of 37.5% by weight, extruded from the outside of the double tubular spinneret, and nitrogen heated to 80.degree. After traveling for 7 mm, the mixture was passed through a coagulating liquid at 15 ° C. in which water, N-methyl-2-pyrrolidone, and polyethylene glycol # 200 were mixed in a weight ratio of 70:15:15 to complete coagulation. . After that, it is washed with water and impregnated with 50% by weight of glycerin, and then dried by a drier to have an inner diameter of 201 μm, a thickness of 21 μm, and a porosity of 78
% Of hollow fiber membrane was obtained. When the inner surface and outer surface of the hollow fiber membrane were observed with an electron microscope (hereinafter, SEM), as shown in FIGS. 3 and 4, both the inner surface and the outer surface had pores and irregularities even at a magnification of 5000 times. It was a smooth structure in which no was observed. Further, the hollow fiber membrane was taken along AA shown in FIG.
When a part of the cross section (FIG. 2) cut along the line (the inside of the enclosing line B in FIG. 2) was observed at a magnification of 200 times, a tissue image was observed inside the film as shown in FIG. It was confirmed that the structure was not uniform. 8,400 hollow fiber membranes were housed in a plastic molded product, and both ends were cured and fixed with an epoxy adhesive to form a module. Blood (hematocrit value 28%, protein concentration 7 g / dl) at 37 ° C. was flowed inside the hollow fiber membrane of the obtained module at a flow rate of 200 m.
1 / min was introduced to evaluate the performance of the hollow fiber membrane. The results were as shown in Table 1.
【0048】(実施例2)ジメチルホルムアミド1重量
%溶液の還元粘度が0.7のポリエーテルスルホンが2
7重量%、ポリビニルピロリドン(K−90)が3重量
%、溶媒としてN−メチル−2−ピロリドン42重量
%、非溶媒としてポリエチレングリコール#200が2
8重量%からなる原料を140℃に加熱して溶かした溶
液を、二重管状紡糸口の外側から押し出し、中心からは
120℃に加熱された窒素を送り込んで中空糸状とし
て、空気中を3mm走行させた後、水、N−メチル−2
−ピロリドン、ポリエチレングリコール#200が7
0:18:12の重量比で混合して成る30℃の凝固性
液体中を通過させ、凝固を完了した。その後、水洗し、
50重量%のグリセリンを含浸させた後、乾燥機にて乾
燥して内径200μm、膜厚30μm、空孔率68%の
中空糸膜を得た。該中空糸膜をSEMで観察したとこ
ろ、実施例1と同様に中空糸の内表面及び外表面は50
00倍の倍率でも孔及び凹凸の認められない平滑構造
で、膜内部は組織像が観察されず均一構造であることが
確認された(図は省略)。得られたモジュールについて
実施例1と同様に中空糸膜の性能評価を行った結果は表
1に示す通りであった。また、上記のモジュールに、3
7℃の血液(ヘマトリット値28%、蛋白質濃度7g/
dl)を流量200ml/分にて、中空糸膜の内側ある
いは外側に導入して、血液濾過を行った場合のモジュー
ルあたりの限外濾過速度(ml/min・mmHg)
は、血液を内側に流した場合25ml/min・mmH
g、外側に流した場合23ml/min・mmHgであ
り、実質的に差がなかった。このことから膜が均一構造
であることが示唆された。Example 2 2% polyether sulfone having a reduced viscosity of 0.7% in a 1% by weight solution of dimethylformamide was used.
7% by weight, 3% by weight of polyvinylpyrrolidone (K-90), 42% by weight of N-methyl-2-pyrrolidone as a solvent, 2% of polyethylene glycol # 200 as a non-solvent
A solution obtained by heating a raw material composed of 8% by weight to 140 ° C. is extruded from the outside of the double tubular spinneret, and nitrogen heated to 120 ° C. is fed from the center to form a hollow fiber, and travels 3 mm in the air. Water, N-methyl-2
-Pyrrolidone, polyethylene glycol # 200 7
The mixture was passed through a solidifying liquid at 30 ° C., which was mixed at a weight ratio of 0:18:12, to complete solidification. After that, wash with water,
After impregnated with 50% by weight of glycerin, it was dried with a dryer to obtain a hollow fiber membrane having an inner diameter of 200 μm, a film thickness of 30 μm, and a porosity of 68%. When the hollow fiber membrane was observed with a SEM, the inner surface and the outer surface of the hollow fiber were 50% as in Example 1.
Even at a magnification of 00, it was confirmed that the film had a uniform structure with no pores and unevenness, and no tissue image was observed inside the film (not shown). The results of the performance evaluation of the hollow fiber membrane performed on the obtained module in the same manner as in Example 1 are as shown in Table 1. In addition, 3
Blood at 7 ° C. (hematrit value 28%, protein concentration 7 g /
dl) is introduced at the flow rate of 200 ml / min inside or outside the hollow fiber membrane, and the ultrafiltration rate per module when blood filtration is performed (ml / min · mmHg)
Is 25 ml / min · mmH when blood flows inside
g, 23 ml / min · mmHg when flowing outside, there was no substantial difference. This suggested that the film had a uniform structure.
【0049】(実施例3)ジメチルホルムアミド1重量
%溶液の還元粘度が0.7のポリエーテルスルホンが2
5重量%、ポリビニルピロリドン(K−90)が3重量
%、溶媒としてN−メチル−2−ピロリドン50重量
%、非溶媒としてトリエチレングリコール#200が1
5重量%及びグリセリン7重量%からなる原料を150
℃に加熱して溶かした溶液を、二重管状紡糸口の外側か
ら押し出し、中心からは100℃に加熱された窒素を送
り込んで中空糸状として、空気中を4mm走行させた
後、水、N−メチル−2−ピロリドン、トリエチレング
リコール、グリセリンが70:21:6:3の重量比で
混合して成る30℃の凝固性液体中を通過させ、凝固を
完了した。その後、水洗し、50重量%のグリセリンを
含浸させた後、乾燥機にて乾燥して内径198μm、膜
厚28μm、空孔率63%の中空糸膜を得た。該中空糸
膜をSEMで観察したところ、実施例1と同様に中空糸
の内表面及び外表面は5000倍の倍率でも孔及び凹凸
の認められない平滑構造で、膜内部は組織像が観察され
ず均一構造であることが確認された(図は省略)。得ら
れたモジュールについて実施例1と同様に中空糸膜の性
能評価を行った結果は表1に示す通りであった。Example 3 2% polyether sulfone having a reduced viscosity of 0.7% in a 1% by weight solution of dimethylformamide was used.
5% by weight, 3% by weight of polyvinylpyrrolidone (K-90), 50% by weight of N-methyl-2-pyrrolidone as a solvent, and 1% of triethylene glycol # 200 as a non-solvent
A raw material consisting of 5% by weight and 7% by weight of glycerin is mixed with 150%
The solution dissolved by heating to 0 ° C. was extruded from the outside of the double tubular spinneret, and nitrogen heated to 100 ° C. was fed from the center to form a hollow fiber, and after traveling 4 mm in the air, water and N- The coagulation was completed by passing through a coagulable liquid at 30 ° C. consisting of a mixture of methyl-2-pyrrolidone, triethylene glycol and glycerin in a weight ratio of 70: 21: 6: 3. Thereafter, the membrane was washed with water, impregnated with 50% by weight of glycerin, and dried with a drier to obtain a hollow fiber membrane having an inner diameter of 198 μm, a thickness of 28 μm, and a porosity of 63%. When the hollow fiber membrane was observed with a SEM, the inner surface and the outer surface of the hollow fiber had a smooth structure with no pores and unevenness even at a magnification of 5000 times as in Example 1, and a tissue image was observed inside the membrane. The structure was confirmed to be uniform (not shown). The results of the performance evaluation of the hollow fiber membrane performed on the obtained module in the same manner as in Example 1 are as shown in Table 1.
【0050】(実施例4)ジメチルホルムアミド1重量
%溶液の還元粘度が0.83のポリエーテルスルホンが
22重量%、ポリビニルピロリドン(K−90)が3重
量%、溶媒としてN−メチル−2−ピロリドン45重量
%、非溶媒としてポリエチレングリコール#200が3
0重量%からなる原料を120℃に加熱して溶かした溶
液を、二重管状紡糸口の外側から押し出し、中心からは
90℃に加熱した窒素を送り込んで中空糸状として、空
気中を5mm走行させた後、水、N−メチル−2−ピロ
リドン、ポリエチレングリコール#200が60:2
4:16の重量比で混合してなる30℃の凝固性液体中
を通過させ凝固を完了した。その後水洗し、50重量%
のグリセリンを含浸させた後、乾燥機にて乾燥し、内径
203μm、膜厚20μm、空孔率78%の中空糸膜を
得た。該中空糸膜をSEMで観察したところ、実施例1
と同様に中空糸の内表面及び外表面は5000倍の倍率
でも孔及び凹凸の認められない平滑構造で、膜内部は組
織像が観察されず均一構造であることが確認された(図
は省略)。得られたモジュールについて実施例1と同様
に中空糸膜の性能評価を行った結果は表1に示す通りで
あった。Example 4 22% by weight of polyether sulfone having a reduced viscosity of 0.83 in a 1% by weight solution of dimethylformamide, 3% by weight of polyvinylpyrrolidone (K-90), and N-methyl-2- as a solvent 45% by weight of pyrrolidone, 3 of polyethylene glycol # 200 as a non-solvent
A solution prepared by heating a 0% by weight raw material to 120 ° C. is extruded from the outside of the double tubular spinneret, and nitrogen heated to 90 ° C. is sent from the center to form a hollow fiber, and is run 5 mm in the air. Water, N-methyl-2-pyrrolidone, polyethylene glycol # 200 at 60: 2
The mixture was passed through a solidifying liquid at 30 ° C. mixed at a weight ratio of 4:16 to complete solidification. After washing with water, 50% by weight
Was impregnated with glycerin and dried with a dryer to obtain a hollow fiber membrane having an inner diameter of 203 μm, a film thickness of 20 μm, and a porosity of 78%. When the hollow fiber membrane was observed by SEM,
Similarly to the above, the inner surface and outer surface of the hollow fiber had a smooth structure in which pores and irregularities were not observed even at a magnification of 5000 times, and it was confirmed that a tissue image was not observed inside the membrane and that the film had a uniform structure (the figure is omitted). ). The results of the performance evaluation of the hollow fiber membrane performed on the obtained module in the same manner as in Example 1 are as shown in Table 1.
【0051】(実施例5)ジメチルホルムアミド1重量
%溶液の還元粘度が0.73のポリエーテルスルホンが
24重量%、ポリビニルピロリドン(K−90)が3重
量%、溶媒としてN−メチル−2−ピロリドン36.5
重量%、非溶媒としてポリエチレングリコール#200
が36.5重量%からなる原料を120℃に加熱して溶
かした溶液を、二重管状紡糸口の外側から押し出し、中
心からは80℃に加熱した窒素を送り込んで中空糸状と
して、空気中を4mm走行させた後、水、N−メチル−
2−ピロリドン、ポリエチレングリコール#200が7
0:15:15の重量比で混合してなる25℃の凝固性
液体中を通過させ凝固を完了した。その後水洗し、50
重量%のグリセリンを含浸させた後、乾燥機にて乾燥
し、内径201μm、膜厚22μm、空孔率76%の中
空糸膜を得た。該中空糸膜をSEMで観察したところ、
実施例1と同様に中空糸の内表面及び外表面は5000
倍の倍率でも孔及び凹凸の認められない平滑構造で、膜
内部は組織像が観察されず均一構造であることが確認さ
れた(図は省略)。得られたモジュールについて実施例
1と同様に中空糸膜の性能評価を行った結果は表1に示
す通りであった。Example 5 A 1% by weight solution of dimethylformamide was 24% by weight of polyether sulfone having a reduced viscosity of 0.73, 3% by weight of polyvinylpyrrolidone (K-90), and N-methyl-2- as a solvent. Pyrrolidone 36.5
% By weight, polyethylene glycol # 200 as non-solvent
Is heated from 120.degree. C. to melt a raw material composed of 36.5% by weight, extruded from the outside of the double tubular spinneret, and nitrogen heated to 80.degree. After running 4 mm, water, N-methyl-
2-pyrrolidone, polyethylene glycol # 200 is 7
The mixture was passed through a solidifying liquid at 25 ° C. mixed at a weight ratio of 0:15:15 to complete solidification. Then wash with water, 50
After impregnating with glycerin of weight%, it was dried with a dryer to obtain a hollow fiber membrane having an inner diameter of 201 μm, a film thickness of 22 μm, and a porosity of 76%. When the hollow fiber membrane was observed by SEM,
As in Example 1, the inner and outer surfaces of the hollow fiber were 5000
It was confirmed that the film had a uniform structure in which no pores and irregularities were observed even at a magnification of ×, and no tissue image was observed inside the film (not shown). The results of the performance evaluation of the hollow fiber membrane performed on the obtained module in the same manner as in Example 1 are as shown in Table 1.
【0052】(比較例1)ジメチルホルムアミド1重量
%溶液の還元粘度が0.52のポリエーテルスルホンが
23重量%、溶媒としてN−メチル−2−ピロリドンが
38.5重量%、非溶媒としてポリエチレングリコール
#200が38.5重量%からなる原料を130℃に加
熱して溶かした溶液を、二重管状紡糸孔の外側から押し
出し、中心からは70℃に加温した窒素を送り込んで中
空糸状として、空気中を2mm走行させた後、水、N−
メチル−2−ピロリドン、ポリエチレングリコール#2
00を70:15:15の重量比で混合して成る30℃
の凝固性液体中を通過させ、凝固を完了した。その後、
水洗し、50重量%のグリセリンを含浸させた後、乾燥
機にて乾燥して内径202μm、膜厚43μm、空孔率
65%の中空糸膜を得た。該中空糸膜の内表面を500
0倍の倍率のSEMで観察したところ、第6図に示すよ
うに内表面にはサブミクロン領域の大きな孔が確認され
た。該中空糸膜の外表面を5000倍の倍率のSEMで
観察したところ、第7図に示すように外表面には孔及び
凹凸が観察された。また、該中空糸膜を第1図に示すA
−A線に添って切断した断面(第2図)の一部(第2図
の囲い線Bの内部)を150倍の倍率で観察したとこ
ろ、第8図に示すように膜内部はフィンガーライク構造
であることが確認された。得られたモジュールについ
て、実施例1と同様に中空糸膜の性能評価を行った結果
は表2に示す通りであった。Comparative Example 1 A 1% by weight solution of dimethylformamide was 23% by weight of polyether sulfone having a reduced viscosity of 0.52, 38.5% by weight of N-methyl-2-pyrrolidone as a solvent, and polyethylene as a non-solvent. A solution obtained by heating a raw material composed of 38.5% by weight of glycol # 200 to 130 ° C. is extruded from the outside of the double tubular spinning hole, and nitrogen heated to 70 ° C. is fed from the center to form a hollow fiber. After running 2 mm in the air, water, N-
Methyl-2-pyrrolidone, polyethylene glycol # 2
30 ° C. by mixing 00 in a weight ratio of 70:15:15
To complete coagulation. afterwards,
After being washed with water and impregnated with 50% by weight of glycerin, it was dried with a drier to obtain a hollow fiber membrane having an inner diameter of 202 μm, a film thickness of 43 μm, and a porosity of 65%. When the inner surface of the hollow fiber membrane is 500
When observed by SEM at a magnification of 0, large holes in the submicron region were confirmed on the inner surface as shown in FIG. When the outer surface of the hollow fiber membrane was observed by SEM at a magnification of 5000 times, pores and irregularities were observed on the outer surface as shown in FIG. Further, the hollow fiber membrane was prepared as shown in FIG.
A part of the cross section (FIG. 2) cut along the line A (FIG. 2) (inside the enclosing line B in FIG. 2) was observed at a magnification of 150 times, and as shown in FIG. The structure was confirmed. The performance of the hollow fiber membrane was evaluated for the obtained module in the same manner as in Example 1, and the results are as shown in Table 2.
【0053】(比較例2)ジメチルホルムアミド1重量
%溶液の還元粘度が0.52のポリエーテルスルホンが
23重量%、溶媒としてN−メチル−2−ピロリドンが
38.5重量%、非溶媒としてポリエチレングリコール
#200が38.5重量%からなる原料を130℃に加
熱して溶かした溶液を、二重管状紡糸口の外側から押し
出し、中心からは40℃に加温された窒素を送り込んで
中空糸状として、空気中を2mm走行させた後、水、N
−メチル−2−ピロリドン、ポリエチレングリコール#
200を70:15:15の重量比で混合して成る30
℃の凝固性液体中を通過させ、凝固を完了した。その
後、水洗し、50重量%のグリセリンを含浸させた後、
乾燥機にて乾燥して内径199μm、膜厚33μm、空
孔率73%の中空糸膜を得た。該中空糸膜をSEMで観
察したところ、比較例1と同様に中空糸の外表面及び内
表面は共に5000倍の倍率でも孔及び/又は凹凸が確
認された(図9、図10)。但し、膜内部は均一構造に
近い構造であることが確認された(図11)。得られた
モジュールについて、実施例1と同様に中空糸膜の性能
評価を行った結果は表2に示す通りであった。Comparative Example 2 23% by weight of polyethersulfone having a reduced viscosity of 0.52 in a 1% by weight solution of dimethylformamide, 38.5% by weight of N-methyl-2-pyrrolidone as a solvent, and polyethylene as a non-solvent A solution obtained by heating a raw material composed of 38.5% by weight of glycol # 200 to 130 ° C. and extruding it from the outside of the double tubular spinneret is extruded, and nitrogen heated to 40 ° C. is fed from the center to form a hollow fiber. After traveling 2 mm in the air, water, N
-Methyl-2-pyrrolidone, polyethylene glycol #
200 mixed at a weight ratio of 70:15:15
The solution was passed through a solidifying liquid at a temperature of 0 ° C. to complete solidification. Then, after washing with water and impregnating 50% by weight of glycerin,
Drying with a dryer yielded a hollow fiber membrane having an inner diameter of 199 μm, a film thickness of 33 μm, and a porosity of 73%. When the hollow fiber membrane was observed by SEM, holes and / or irregularities were confirmed on both the outer surface and the inner surface of the hollow fiber at a magnification of 5000 times as in Comparative Example 1 (FIGS. 9 and 10). However, it was confirmed that the inside of the film had a structure close to a uniform structure (FIG. 11). The performance of the hollow fiber membrane was evaluated for the obtained module in the same manner as in Example 1, and the results are as shown in Table 2.
【0054】(比較例3)ジメチルホルムアミド1重量
%溶液の還元粘度が0.48のポリエーテルスルホンが
23重量%、ポリビニルピロリドン(K−90)が3重
量%、溶媒としてN−メチル−2−ピロリドン37重量
%、非溶媒としてポリエチレングリコール#200が3
7重量%からなる原料を120℃に加熱して溶かした溶
液を、二重管状紡糸口の外側から押し出し、中心からは
80℃に加熱した窒素を送り込んで中空糸状として、空
気中を4mm走行させた後、水、N−メチル−2−ピロ
リドン、ポリエチレングリコール#200が70:1
5:15の重量比で混合してなる25℃の凝固性液体中
を通過させ凝固を完了した。その後水洗し、50重量%
のグリセリンを含浸させた後、乾燥機にて乾燥し、内径
201μm、膜厚23μm、空孔率75%の中空糸膜を
得た。該中空糸膜の内表面をSEMで観察したところ、
サブミクロン領域の大きな孔が確認された。また、該中
空糸を第1図に示すA−A線に沿って切断した断面(第
2図)の一部(第2図の囲い線Bの内部)を200倍の
倍率で観察したところ、膜内は均一構造に近い構造であ
ることが確認された(図は省略)。得られたモジュール
について、実施例1と同様に中空糸膜の性能評価を行っ
た結果は表2に示す通りであった。Comparative Example 3 A 1% by weight solution of dimethylformamide was 23% by weight of polyether sulfone having a reduced viscosity of 0.48, 3% by weight of polyvinylpyrrolidone (K-90), and N-methyl-2- as a solvent. 37% by weight of pyrrolidone, 3 of polyethylene glycol # 200 as a non-solvent
A solution obtained by heating a 7 wt% raw material to 120 ° C. and extruding the solution was extruded from the outside of the double tubular spinneret, and nitrogen heated to 80 ° C. was fed from the center to form a hollow fiber, which was run 4 mm in the air. After that, water, N-methyl-2-pyrrolidone, polyethylene glycol # 200 were mixed at 70: 1.
The mixture was passed through a solidifying liquid at 25 ° C. mixed at a weight ratio of 5:15 to complete solidification. After washing with water, 50% by weight
Was impregnated with glycerin and dried with a drier to obtain a hollow fiber membrane having an inner diameter of 201 μm, a film thickness of 23 μm, and a porosity of 75%. When the inner surface of the hollow fiber membrane was observed by SEM,
Large pores in the submicron region were confirmed. In addition, when a part of the cross section (FIG. 2) of the hollow fiber cut along the line AA shown in FIG. 1 (inside the enclosing line B in FIG. 2) was observed at a magnification of 200 times, It was confirmed that the inside of the film had a structure close to a uniform structure (not shown). The performance of the hollow fiber membrane was evaluated for the obtained module in the same manner as in Example 1, and the results are as shown in Table 2.
【0055】(比較例4)ジメチルホルムアミド1重量
%溶液の還元粘度が0.51のポリエーテルスルホンが
24重量%、溶媒としてN−メチル−2−ピロリドン3
8重量%、非溶媒としてポリエチレングリコール#20
0が38重量%からなる原料を130℃に加熱して溶か
した溶液を、二重管状紡糸口の外側から押し出し、中心
からは70℃に加熱した窒素を送り込んで中空糸状とし
て、空気中を3mm走行させた後、水、N−メチル−2
−ピロリドン、ポリエチレングリコール#200が7
0:15:15の重量比で混合してなる20℃の凝固性
液体中を通過させ凝固を完了した。その後水洗し、50
重量%のグリセリンを含浸させた後、乾燥機にて乾燥
し、内径200μm、膜厚24μm、空孔率72%の中
空糸膜を得た。該中空糸膜の内表面をSEMで観察した
ところ、内表面及にはサブミクロン領域の大きな孔が確
認された。また、該中空糸を第1図に示すA−A線に沿
って切断した断面(第2図)の一部(第2図の囲い線B
の内部)を200倍の倍率で観察したところ、膜内はフ
ィンガーライク構造であることが確認された(図は省
略)。得られたモジュールについて、実施例1と同様に
中空糸膜の性能評価を行った結果は表2に示す通りであ
った。Comparative Example 4 A 1% by weight solution of dimethylformamide was 24% by weight of polyether sulfone having a reduced viscosity of 0.51, and N-methyl-2-pyrrolidone 3 was used as a solvent.
8% by weight, polyethylene glycol # 20 as non-solvent
A solution obtained by heating a raw material containing 0% by weight to 38% by weight at 130 ° C. is extruded from the outside of the double tubular spinneret, and nitrogen heated at 70 ° C. is fed from the center to form a hollow fiber, and 3 mm in the air. After running, water, N-methyl-2
-Pyrrolidone, polyethylene glycol # 200 7
The mixture was passed through a solidifying liquid at 20 ° C. mixed at a weight ratio of 0:15:15 to complete solidification. Then wash with water, 50
After impregnating with glycerin of weight%, it was dried with a drier to obtain a hollow fiber membrane having an inner diameter of 200 μm, a film thickness of 24 μm, and a porosity of 72%. When the inner surface of the hollow fiber membrane was observed by SEM, large pores in the submicron region were confirmed on the inner surface and the inner surface. A part of a cross section (FIG. 2) of the hollow fiber cut along the line AA shown in FIG. 1 (enclosed line B in FIG. 2).
Was observed at a magnification of 200 times, and it was confirmed that the inside of the film had a finger-like structure (not shown). The performance of the hollow fiber membrane was evaluated for the obtained module in the same manner as in Example 1, and the results are as shown in Table 2.
【0056】[0056]
【表1】 [Table 1]
【0057】[0057]
【表2】 [Table 2]
【0058】[0058]
【発明の効果】本発明は上記のような構成・説明から明
かなように、各種液体の透析、濾過処理、つまり、限外
濾過、逆浸透、ガス分離、血液浄化等に好適に用いるこ
とができる中空糸型選択分離膜を提供するものである。
すなわち、本発明の中空糸型選択分離膜を用いた透析及
び/又は濾過モジュールは経時的に安定した大量除水が
可能で、また大量除水時でも効率よく溶質を透析/濾過
除去することができる。このように本発明の中空糸型選
択分離膜を用いた透析及び/又は濾過モジュールは経時
的に安定した、濾過性能及び分離性能を発揮することが
できる。よって、本発明の効果は大である。As is clear from the above constitution and explanation, the present invention can be suitably used for dialysis and filtration treatment of various liquids, that is, ultrafiltration, reverse osmosis, gas separation, blood purification and the like. The present invention provides a hollow fiber type selective separation membrane that can be used.
That is, the dialysis and / or filtration module using the hollow fiber type selective separation membrane of the present invention can perform a large amount of water removal stably over time, and can efficiently dialyze / filter and remove solutes even during a large amount of water removal. it can. As described above, the dialysis and / or filtration module using the hollow fiber type selective separation membrane of the present invention can exhibit stable filtration performance and separation performance over time. Therefore, the effect of the present invention is great.
【図1】中空糸型中空糸型選択分離膜の斜視図の概略図
である。FIG. 1 is a schematic view of a perspective view of a hollow fiber type hollow fiber type selective separation membrane.
【図2】図1の中空糸型中空糸型選択分離膜を図1のA
−A線で切断した斜断面図の概略図である。2 shows the hollow fiber type hollow fiber type selective separation membrane of FIG.
It is the schematic of the oblique sectional view cut | disconnected by the -A line.
【図3】本願実施例1で得られた中空糸型中空糸型選択
分離膜の内表面の5000倍の電子顕微鏡写真である。FIG. 3 is a 5000 × electron micrograph of the inner surface of the hollow fiber type hollow fiber type selective separation membrane obtained in Example 1 of the present application.
【図4】本願実施例1で得られた中空糸型中空糸型選択
分離膜の外表面の5000倍の電子顕微鏡写真である。FIG. 4 is a 5000 × electron micrograph of the outer surface of the hollow fiber type hollow fiber type selective separation membrane obtained in Example 1 of the present application.
【図5】本願実施例1で得られた中空糸型中空糸型選択
分離膜の斜断面の一部の300倍の電子顕微鏡写真であ
る。FIG. 5 is a 300 × electron microscope photograph of a part of an oblique cross section of the hollow fiber type hollow fiber type selective separation membrane obtained in Example 1 of the present application.
【図6】本願比較例1で得られた中空糸型中空糸型選択
分離膜の内表面の5000倍の電子顕微鏡写真である。FIG. 6 is a 5000 × electron microscope photograph of the inner surface of the hollow fiber type hollow fiber type selective separation membrane obtained in Comparative Example 1 of the present application.
【図7】本願比較例1で得られた中空糸型中空糸型選択
分離膜の外表面の5000倍の電子顕微鏡写真である。FIG. 7 is a 5000 × electron micrograph of the outer surface of the hollow fiber type hollow fiber type selective separation membrane obtained in Comparative Example 1 of the present application.
【図8】本願比較例1で得られた中空糸型中空糸型選択
分離膜の斜断面の一部の150倍の電子顕微鏡写真であ
る。FIG. 8 is a 150 × electron microscope photograph of a part of an oblique cross section of the hollow fiber type hollow fiber type selective separation membrane obtained in Comparative Example 1 of the present application.
【図9】本願比較例2で得られた中空糸型中空糸型選択
分離膜の内表面の5000倍の電子顕微鏡写真である。FIG. 9 is a 5000 × electron micrograph of the inner surface of the hollow fiber type hollow fiber type selective separation membrane obtained in Comparative Example 2 of the present application.
【図10】本願比較例2で得られた中空糸型中空糸型選
択分離膜の外表面の5000倍の電子顕微鏡写真であ
る。FIG. 10 is a 5000 × electron micrograph of the outer surface of the hollow fiber type hollow fiber type selective separation membrane obtained in Comparative Example 2 of the present application.
【図11】本願比較例2で得られた中空糸型中空糸型選
択分離膜の斜断面の一部の300倍の電子顕微鏡写真で
ある。FIG. 11 is a 300 × electron micrograph of a part of an oblique cross section of the hollow fiber type hollow fiber type selective separation membrane obtained in Comparative Example 2 of the present application.
Claims (8)
300μm、空孔率が50〜85%のポリスルホン系高
分子を含む中空糸型選択分離膜であって、該ポリスルホ
ン系高分子のジメチルホルムアミド1重量パーセント溶
液中の還元粘度が0.55〜0.85であることを特徴
とする中空糸型選択分離膜。1. A film having a thickness of 10 to 35 μm and an inner diameter of 100 to
A hollow fiber type selective separation membrane containing a polysulfone polymer having a porosity of 300 μm and a porosity of 50 to 85%, wherein the polysulfone polymer has a reduced viscosity in a 1% by weight solution of dimethylformamide of 0.55 to 0.5%. 85: a hollow fiber type selective separation membrane,
項1の中空糸型選択分離膜。2. The hollow fiber type selective separation membrane according to claim 1, comprising a hydrophilic polymer.
あることを特徴とする請求項2の中空糸型選択分離膜。3. The hollow fiber type selective separation membrane according to claim 2, wherein the hydrophilic polymer is polyvinylpyrrolidone.
求項1乃至3の中空糸型選択分離膜。4. The hollow fiber type selective separation membrane according to claim 1, further comprising a membrane structure retention agent.
特徴とする請求項4の中空糸型選択分離膜。5. The hollow fiber type selective separation membrane according to claim 4, wherein the membrane structure retaining agent is glycerin.
とき明らかに認められる孔及び凹凸が存在せず、且つ、
200倍に拡大して膜断面を観察するとき実質的に均一
であることを特徴とする請求項1乃至5の中空糸型選択
分離膜。6. There are no pores and irregularities clearly observed when observing the film surface at a magnification of 5000 times, and
6. The hollow fiber type selective separation membrane according to claim 1, wherein the membrane is substantially uniform when the membrane cross section is observed at a magnification of 200 times.
ュールにヘマトクリット25〜30%、蛋白質濃度6〜
7g/dlの牛血液を流速200ml/minで流し、
濾過流速10ml/minで血液濾過を行ったときのβ
2-ミクログロブリンの篩い係数に対する、濾過流速50
ml/minで血液濾過を行ったときのβ2-ミクログロ
ブリンの篩い係数の比が60%以上であることを特徴と
する請求項1乃至6の中空糸型選択分離膜。7. The module filled with the hollow fiber type selective separation membrane has a hematocrit of 25 to 30% and a protein concentration of 6 to 30%.
Flow 7 g / dl bovine blood at a flow rate of 200 ml / min,
Β when blood filtration was performed at a filtration flow rate of 10 ml / min
Filtration flow rate 50 for 2-microglobulin sieving coefficient
The hollow fiber type selective separation membrane according to any one of claims 1 to 6, wherein the ratio of the sieving coefficient of β2-microglobulin is 60% or more when blood filtration is performed at ml / min.
ュールにヘマトクリット25〜30%、蛋白質濃度6〜
7g/dlの牛血液を流速200ml/minで流し、
濾過流速50ml/minで血液濾過を行ったときの、
濾過開始後10分時点での限外濾過速度に対する、濾過
開始後5時間時点での限外濾過速度の比が70%以上で
あることを特徴とする請求項1乃至7の中空糸型選択分
離膜。8. The module filled with the hollow fiber type selective separation membrane has a hematocrit of 25 to 30% and a protein concentration of 6 to
Flow 7 g / dl bovine blood at a flow rate of 200 ml / min,
When blood filtration was performed at a filtration flow rate of 50 ml / min,
8. The hollow fiber type selective separation according to claim 1, wherein the ratio of the ultrafiltration speed at 5 hours after the start of filtration to the ultrafiltration speed at 10 minutes after the start of filtration is 70% or more. film.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP26482696A JPH10109023A (en) | 1996-10-04 | 1996-10-04 | Hollow fiber type selective separation membrane |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP26482696A JPH10109023A (en) | 1996-10-04 | 1996-10-04 | Hollow fiber type selective separation membrane |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH10109023A true JPH10109023A (en) | 1998-04-28 |
Family
ID=17408751
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP26482696A Pending JPH10109023A (en) | 1996-10-04 | 1996-10-04 | Hollow fiber type selective separation membrane |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH10109023A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005342095A (en) * | 2004-06-01 | 2005-12-15 | Toyobo Co Ltd | High water-permeable hollow fiber membrane type blood purifier |
| JP2005348874A (en) * | 2004-06-09 | 2005-12-22 | Toyobo Co Ltd | Polysulfone permselective hollow fiber membrane |
| JP2006187768A (en) * | 2004-12-09 | 2006-07-20 | Toray Ind Inc | A method for producing a polysulfone-based hollow fiber membrane and a method for producing a medical use module using the same. |
| US9616393B2 (en) | 2007-12-06 | 2017-04-11 | Asahi Kasei Medical Co., Ltd. | Porous hollow fiber membrane for treating blood |
-
1996
- 1996-10-04 JP JP26482696A patent/JPH10109023A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005342095A (en) * | 2004-06-01 | 2005-12-15 | Toyobo Co Ltd | High water-permeable hollow fiber membrane type blood purifier |
| JP2005348874A (en) * | 2004-06-09 | 2005-12-22 | Toyobo Co Ltd | Polysulfone permselective hollow fiber membrane |
| JP2006187768A (en) * | 2004-12-09 | 2006-07-20 | Toray Ind Inc | A method for producing a polysulfone-based hollow fiber membrane and a method for producing a medical use module using the same. |
| US9616393B2 (en) | 2007-12-06 | 2017-04-11 | Asahi Kasei Medical Co., Ltd. | Porous hollow fiber membrane for treating blood |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1311884C (en) | Polysulfone hollow fiber membrane and process for making the same | |
| JP5504560B2 (en) | Hollow fiber membrane for liquid processing | |
| EP2845641B1 (en) | Permselective asymmetric membranes with high molecular weight polyvinylpyrrolidone, the preparation and use thereof | |
| US20060108288A1 (en) | Plasma purification membrane and plasma purification system | |
| US6042783A (en) | Hollow yarn membrane used for blood purification and blood purifier | |
| JP2792556B2 (en) | Blood purification module, blood purification membrane and method for producing the same | |
| EP0716859B1 (en) | Module for blood purification, blood purification membrane and its production | |
| JPH10108907A (en) | Membrane for hemocatharsis, its preparation and module for hemocatharsis | |
| CN101400388A (en) | Hollow fiber membrane with excellent performance stability and blood purifier and method for producing hollow fiber membrane | |
| US10888823B2 (en) | Membrane with improved permeability and selectivity | |
| AU672856B2 (en) | High flux hollow fiber membrane | |
| JPH09220455A (en) | Hollow yarn type selective separation membrane | |
| JP2703266B2 (en) | Polysulfone hollow fiber membrane and method for producing the same | |
| JP4103037B2 (en) | Diaphragm cleaning hollow fiber membrane and method for producing the same | |
| JPH10109023A (en) | Hollow fiber type selective separation membrane | |
| JPH11309355A (en) | Polysulfone hollow fiber type blood purifying membrane and its production | |
| WO1996035504A1 (en) | Hollow-fiber membrane of polysulfone polymer and process for the production thereof | |
| JP7131038B2 (en) | Hollow fiber membrane for ascites filtration | |
| JP2008246402A (en) | Hollow fiber type blood purification membrane and method of manufacturing the same | |
| JP2001038172A (en) | Hollow fiber membrane type selective separation membrane | |
| JP4190361B2 (en) | Hollow fiber type body fluid treatment device, hollow fiber bundle used therefor, and method for producing them | |
| JP4093134B2 (en) | Hollow fiber blood purification membrane | |
| JPH08970A (en) | Hollow fiber membrane | |
| JP2001038171A (en) | Hollow fiber membrane | |
| JP4386607B2 (en) | Polysulfone blood purification membrane production method and polysulfone blood purification membrane |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20050127 |
|
| A131 | Notification of reasons for refusal |
Effective date: 20050203 Free format text: JAPANESE INTERMEDIATE CODE: A131 |
|
| A02 | Decision of refusal |
Effective date: 20050602 Free format text: JAPANESE INTERMEDIATE CODE: A02 |